In this article, we will be taking a look at the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now.

Investors looking for substantial potential without making a sizable initial investment continue to be drawn to inexpensive stocks. Finding quality opportunities is still difficult in an unpredictable macroeconomic climate, even if many low-cost stocks operate in high-growth industries that profit from long-term structural trends.

The Middle East war has been one of 2026’s defining issues. In its June 15 article, “Iran deal could expand market gains, with consumer shares, small caps seen benefiting,” Reuters stated that lower oil prices and easing geopolitical tensions could boost consumer spending, lower Treasury yields and inflationary pressures, and strengthen economically sensitive sectors like consumer stocks, small caps, and energy-dependent markets. Strategists at JPMorgan observed,

“If our positive macro view plays out – underpinned by strong earnings, stable inflation expectations, and an easing of geopolitical risks in the second half – cyclicals should remain well positioned to outperform through year-end.”

However, uncertainty resurfaced on June 20 when Reuters reported that Iran had closed the Strait of Hormuz following suspected ceasefire violations.

Many market experts are still positive about stocks in spite of these occurrences. While maintaining a preference for U.S. large-cap growth stocks driven by attractive valuations and AI-powered earnings, T. Rowe Price’s Sébastien Page stated in an interview with CNBC on May 13 that record market highs are not trustworthy sell signals, pointing out that expected S&P 500 earnings growth increased from 13% at the end of March to 27%. Chris Veronne of Strategas observed weakness in consumer stocks and banks on May 12, but pointed out that there was little rotation into defensive sectors, indicating that investors had not generally become risk-averse.

In a similar vein, Callanish Capital CEO Haig Bathgate told CNBC on May 7 that long-term performance is influenced by things like artificial intelligence (AI), capital expenditure cycles, and global energy trends, and that geopolitical conflicts usually cause short-term volatility rather than long-term market harm. Scott Chronert of Citi stated on CNBC’s Closing Bell on March 24 that while sentiment has improved due to the lessening of tensions, liquidity, interest rates, oil prices, currency volatility, earnings, and broader macroeconomic fundamentals would ultimately determine the market’s longer-term trajectory.

Together, these perspectives imply that long-term stock performance is still influenced by earnings growth, policy, innovation, and economic fundamentals, even though geopolitical events can momentarily affect sentiment and market timing.

With that said, let’s take a look at the best up and coming stocks.

Our Methodology

For our methodology, we identified pharmaceutical companies that went public within the last five years. From this list, we selected companies with the most recent news and significant developments. We then ranked these companies based on their total number of hedge fund holders as of Q1 2026, according to the Insider Monkey database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

Here is our list of the 8 best up-and-coming pharmaceutical stocks to buy now.

8. Eikon Therapeutics, Inc. (NASDAQ:EIKN)

Number of Hedge Fund Holders: 12

Eikon Therapeutics, Inc. (NASDAQ:EIKN) is one of the best up and coming stocks on our list.

TheFly reported on June 3 that BofA Securities lowered its price target for EIKN to $32 from $34 while maintaining a Buy rating on the shares. The firm noted that the company’s first-quarter results showed steady advancement in its development initiatives, despite the report being relatively limited in major updates. The revised price target reflected an updated share count assessment.

Eikon Therapeutics, Inc. (NASDAQ:EIKN) reached an important market milestone on June 25 as the company confirmed its upcoming inclusion in the Russell 3000 Index. The addition will take place following the annual reconstitution of the index and will become effective after the close of trading in the U.S. market on June 26, 2026. Being included in the Russell 3000 Index places EIKN among a broader group of publicly traded companies tracked by investors and institutions, potentially increasing visibility and market exposure. This development reflects the company’s continued growth and recognition within the broader U.S. equity market.

Eikon Therapeutics, Inc. (NASDAQ:EIKN) is a clinical-stage biopharmaceutical company developing breakthrough medicines by combining super-resolution microscopy, engineering, and machine learning to study protein dynamics and discover new drug targets for oncology and neurological diseases.

7. AgomAB Therapeutics NV (NASDAQ:AGMB)

Number of Hedge Fund Holders: 16

AgomAB Therapeutics NV (NASDAQ:AGMB) is one of the best up and coming stocks on our list.

TheFly reported on June 22 that H.C. Wainwright initiated coverage of AGMB with a Buy rating and assigned a $35 price target. The firm highlighted that AGMB’s two clinical programs are designed to deliver targeted drug activity within affected tissues while minimizing systemic exposure through rapid inactivation after absorption. The company’s approach aims to utilize the antifibrotic potential of ALK5 inhibition across conditions, including fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis, supporting the potential of its therapeutic pipeline.

Later, on June 23,  AgomAB Therapeutics NV (NASDAQ:AGMB) announced the planned Phase 2b NOV-ERA trial evaluating ontunisertib, an investigational oral ALK5 inhibitor designed for the potential treatment of fibrostenosing Crohn’s disease. The company confirmed alignment with the FDA on the trial framework, including the primary endpoint focused on endoscopic passability at Week 24 and additional secondary measures. The study protocol has been submitted, with regulatory progress also advancing through approvals in the U.S. and Canada. Agomab expects to begin the trial in the second half of 2026, with the global randomized study planned to evaluate the safety and effectiveness of ontunisertib in up to 320 adult patients.

AgomAB Therapeutics NV (NASDAQ:AGMB) is a clinical-stage biotech company developing therapies for fibro-inflammatory and autoimmune diseases using small molecules and regenerative antibodies to reduce inflammation and restore organ function.